O.Y. Fofanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
O.Y. Fofanova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- I. G. Labyak
Івано-Франківський національний медичний університет, кафедра патологічної анатомії, м. Івано-Франківськ, Україна
2 shared publications - Z. Ya. Guryk
Ivano-Frankivsk National Medical University
2 shared publications - Elvira Oleksandrivna Kindrativ
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
1 shared publication - O.M. Rudyak
Ivano-Frankivsk National Medical University, Ivano-Frankivsk
1 shared publication - Y.Y. Sikoryn
Ivano-Frankivsk National Medical University
1 shared publication - Вiктоpiя Василiвна Феденько
Івано-Франківський національний медичний університет
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 113-118
КЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА
The problem of non-alcoholic steatohepatitis (NASH) is becoming increasingly significant, with the number of patients suffering from this disease growing every year worldwide. It has been established that one of the causes of the development of non-alcoholic steatohepatitis (NASH) is metabolic dysfunction in the human body, which manifests in the presence of metabolic syndrome. Additionally, the number of complications such as chronic cholecystitis (both calculous and non-calculous) is increasing, particularly among patients with metabolic syndrome. Primary NASH is a chronic inflammatory liver disease that develops in the background of non-alcoholic fatty liver disease (NAFLD) and is characterised by progressive hepatocellular damage. Comorbid pathology of the gallbladder (GB) is an important factor that complicates the course of primary NASH. Disorders of GB motility and increased levels of bile acids in the blood contribute to increased oxidative stress and chronic inflammation in the liver. Comorbid GB pathology, such as chronic cholecystitis or gallstone disease, significantly complicates the clinical picture of NASH and can affect its morphological features, as well as create additional diagnostic and therapeutic difficulties. The main clinical and morphological forms of NAFLD include: Macrovesicular fatty liver disease without fibrosis, with minimal inflammatory changes, for which progression is not characteristic; Microvesicular fatty liver disease with moderate centrilobular mixed inflammatory infiltrates and the presence of moderate fibrosis, which is characterised by slow progression, although in some cases it can lead to steatogenic cirrhosis; Subacute (subfulminant) NASH, in which fatty liver disease is observed (more often of the macro-microvesicular type) with the development of submassive, central-central bridge-like necroses with mixed inflammatory infiltrates. Morphological changes in NASH include steatosis, which is the accumulation of fat in hepatocytes (both macrovesicular and microvesicular), ballooning degeneration of hepatocytes (enlargement of hepatocytes with cytoplasmic clearing), inflammation (infiltration of liver tissue by lymphocytes and other inflammatory cells), and fibrosis (collagen deposition in the liver, which can progress to cirrhosis). In the presence of comorbid gallbladder pathology, additional morphological changes associated with cholestasis may be observed: accumulation of bile in hepatocytes and bile capillaries, and proliferation of bile ducts. Such patients have a more active inflammatory process in the liver, more severe fibrosis and necrosis of hepatocytes. Effective treatment of NASH in the presence of comorbid GB pathology requires a comprehensive approach, including the correction of bile duct disorders and antioxidant therapy. Early diagnosis and an integrated treatment strategy, including lifestyle changes, medication therapy, and, if necessary, surgical intervention, are crucial for preventing the progression of the disease and the development of serious complications such as cirrhosis and hepatocellular carcinoma. Further research should focus on developing individualized therapy regimens for NASH considering comorbid gallbladder pathology, as well as studying the mechanisms of bile acids’ effect on the progression of inflammation and liver fibrosis.
- 1 July 2025
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 113-118
Open AccessКЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА
The problem of non-alcoholic steatohepatitis (NASH) is becoming increasingly significant, with the number of patients suffering from this disease growing every year worldwide. It has been established that one of the causes of the development of non-alcoholic steatohepatitis (NASH) is metabolic dysfunction in the human body, which manifests in the presence of metabolic syndrome. Additionally, the number of complications such as chronic cholecystitis (both calculous and non-calculous) is increasing, particularly among patients with metabolic syndrome. Primary NASH is a chronic inflammatory liver disease that develops in the background of non-alcoholic fatty liver disease (NAFLD) and is characterised by progressive hepatocellular damage. Comorbid pathology of the gallbladder (GB) is an important factor that complicates the course of primary NASH. Disorders of GB motility and increased levels of bile acids in the blood contribute to increased oxidative stress and chronic inflammation in the liver. Comorbid GB pathology, such as chronic cholecystitis or gallstone disease, significantly complicates the clinical picture of NASH and can affect its morphological features, as well as create additional diagnostic and therapeutic difficulties. The main clinical and morphological forms of NAFLD include: Macrovesicular fatty liver disease without fibrosis, with minimal inflammatory changes, for which progression is not characteristic; Microvesicular fatty liver disease with moderate centrilobular mixed inflammatory infiltrates and the presence of moderate fibrosis, which is characterised by slow progression, although in some cases it can lead to steatogenic cirrhosis; Subacute (subfulminant) NASH, in which fatty liver disease is observed (more often of the macro-microvesicular type) with the development of submassive, central-central bridge-like necroses with mixed inflammatory infiltrates. Morphological changes in NASH include steatosis, which is the accumulation of fat in hepatocytes (both macrovesicular and microvesicular), ballooning degeneration of hepatocytes (enlargement of hepatocytes with cytoplasmic clearing), inflammation (infiltration of liver tissue by lymphocytes and other inflammatory cells), and fibrosis (collagen deposition in the liver, which can progress to cirrhosis). In the presence of comorbid gallbladder pathology, additional morphological changes associated with cholestasis may be observed: accumulation of bile in hepatocytes and bile capillaries, and proliferation of bile ducts. Such patients have a more active inflammatory process in the liver, more severe fibrosis and necrosis of hepatocytes. Effective treatment of NASH in the presence of comorbid GB pathology requires a comprehensive approach, including the correction of bile duct disorders and antioxidant therapy. Early diagnosis and an integrated treatment strategy, including lifestyle changes, medication therapy, and, if necessary, surgical intervention, are crucial for preventing the progression of the disease and the development of serious complications such as cirrhosis and hepatocellular carcinoma. Further research should focus on developing individualized therapy regimens for NASH considering comorbid gallbladder pathology, as well as studying the mechanisms of bile acids’ effect on the progression of inflammation and liver fibrosis.
- Open Access
- 28 June 2025
- Published by Group of Companies Med Expert, LLC in Paediatric Surgery. Ukraine
- No. 2(87),p. 103-109
Clinical and morphologic aspects of noncompact left ventricular cardiomyopathy in the pediatric patient: a clinical case report
Left ventricular noncompaction cardiomyopathy (LVNC) is a rare genetic cardiomyopathy. The disease has a wide range of clinical manifestations, from asymptomatic conditions to serious cardiovascular complications, making its diagnosis and treatment difficult. The aim of this study was to demonstrate the clinical and morphologic aspects of noncompact LVNC in a child and to analyze the current principles of diagnosis of this disease. We present a clinical case of LVNC (spongy) in a child aged 3 years 9 months. Postmortem examination of the child's body was performed in the Pathology Department of the MNPE “Regional Clinical Hospital of the Ivano-Frankivsk Regional Council”. Histological sections of the heart were stained with hematoxylin and eosin and Van Gieson's picrofuchsin. Microscopic examination and photography of samples were performed using an Olympus CX23 light-optical microscope with an LC30 digital CMOS camera and cell Sens Entry software. The presented clinical case allowed us to identify the main pathomorphologic criteria of LVNC: hypertrabecular "spongy" myocardium, hypertrophy of muscle fibers, pleomorphism of cardiac myocytes, endocardial fibrosis, and small-focal myocardial sclerosis. Despite the lack of standardized methods for diagnosing LVNC, ultrasound, echocardiography, magnetic resonance, and cardiac computed tomography are traditional and widely used. Genetic evaluation of cardiomyopathies is an important clinical priority. Genetic testing and phenotyping will allow appropriate treatment of specific LVNC targets, thereby improving survival, reducing morbidity, and improving quality of life. The research was carried out in accordance with the principles of the Declaration of Helsinki. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 28 June 2025
- Published by Group of Companies Med Expert, LLC in Paediatric Surgery. Ukraine
- No. 2(87),p. 103-109
Open AccessClinical and morphologic aspects of noncompact left ventricular cardiomyopathy in the pediatric patient: a clinical case report
Left ventricular noncompaction cardiomyopathy (LVNC) is a rare genetic cardiomyopathy. The disease has a wide range of clinical manifestations, from asymptomatic conditions to serious cardiovascular complications, making its diagnosis and treatment difficult. The aim of this study was to demonstrate the clinical and morphologic aspects of noncompact LVNC in a child and to analyze the current principles of diagnosis of this disease. We present a clinical case of LVNC (spongy) in a child aged 3 years 9 months. Postmortem examination of the child's body was performed in the Pathology Department of the MNPE “Regional Clinical Hospital of the Ivano-Frankivsk Regional Council”. Histological sections of the heart were stained with hematoxylin and eosin and Van Gieson's picrofuchsin. Microscopic examination and photography of samples were performed using an Olympus CX23 light-optical microscope with an LC30 digital CMOS camera and cell Sens Entry software. The presented clinical case allowed us to identify the main pathomorphologic criteria of LVNC: hypertrabecular "spongy" myocardium, hypertrophy of muscle fibers, pleomorphism of cardiac myocytes, endocardial fibrosis, and small-focal myocardial sclerosis. Despite the lack of standardized methods for diagnosing LVNC, ultrasound, echocardiography, magnetic resonance, and cardiac computed tomography are traditional and widely used. Genetic evaluation of cardiomyopathies is an important clinical priority. Genetic testing and phenotyping will allow appropriate treatment of specific LVNC targets, thereby improving survival, reducing morbidity, and improving quality of life. The research was carried out in accordance with the principles of the Declaration of Helsinki. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.